NCT03358602

Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer

Radiotherapy Versus Elective Neck Dissection for Management of Cervical Nodes in Clinical T1/2N0 Supraglottic Squamous Cell Carcinoma

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 158 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Supraglottic cancer is a main type of laryngeal carcinoma, which is one of the most common head and neck tumors. Cervical nodal metastasis is an important prognostic factor in supraglottic cancer. Current management, following the US National Comprehensive Cancer Network guidelines for T1-2, N0 supraglottic cancer (NCCN 2017), is either definitive radiotherapy or primary surgery with or without neck dissection. The optimal neck treatments strategy remains unclear in clinical settings owing to the limitation of a small number of retrospective studies and a lack of prospective trials. The investigators conducted a prospective, randomised trial to compare radiotherapy with neck dissection.

Conditions

• Supraglottic Cancer

Interventions

Type	Name	Description
RADIATION	Radiotherapy	Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
PROCEDURE	Selective neck dissection	Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes

Timeline

• Start date: 2017-12-20
• Primary completion: 2025-11-01
• Completion: 2027-11-01
• First posted: 2017-11-30
• Last updated: 2017-12-12

Locations

1 site across 1 country: China